MIRA Pharmaceuticals (MIRA) to Release Earnings on Friday

MIRA Pharmaceuticals (NASDAQ:MIRA) is projected to release its results before the market opens on Friday, March 27th. Analysts expect MIRA Pharmaceuticals to post earnings of ($0.04) per share for the quarter.

MIRA Pharmaceuticals Trading Down 8.1%

NASDAQ:MIRA opened at $1.02 on Friday. MIRA Pharmaceuticals has a 12 month low of $0.73 and a 12 month high of $2.45. The stock has a market capitalization of $42.72 million, a price-to-earnings ratio of -0.67 and a beta of 1.78. The firm has a fifty day simple moving average of $1.27 and a two-hundred day simple moving average of $1.39.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MIRA. Geode Capital Management LLC raised its position in MIRA Pharmaceuticals by 100.0% in the 4th quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares during the last quarter. Two Sigma Investments LP lifted its stake in MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares in the last quarter. Creative Planning purchased a new position in MIRA Pharmaceuticals during the 2nd quarter worth $27,000. Finally, XTX Topco Ltd purchased a new position in MIRA Pharmaceuticals during the 2nd quarter worth $26,000. Institutional investors own 35.16% of the company’s stock.

Wall Street Analysts Forecast Growth

MIRA has been the subject of several research reports. Rodman & Renshaw assumed coverage on MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Monday, December 29th. Finally, Wall Street Zen cut MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.